Halozyme Therapeutics Inc (HALO)

Fixed asset turnover

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	US$ in thousands	1,015,320	829,253	660,116	443,310	267,594
Property, plant and equipment	US$ in thousands	—	—	75,570	8,794	10,593
Fixed asset turnover		—	—	8.74	50.41	25.26

December 31, 2024 calculation

Fixed asset turnover = Revenue ÷ Property, plant and equipment
= $1,015,320K ÷ $—K
= —

The fixed asset turnover ratio is a measure of how efficiently a company generates revenue from its fixed assets. Looking at the data provided for Halozyme Therapeutics Inc, we observe significant fluctuations in the fixed asset turnover ratio over the years.

In December 31, 2020, the fixed asset turnover ratio was 25.26, indicating that for every dollar invested in fixed assets, the company generated $25.26 in revenue. This high ratio suggests good asset utilization efficiency during that period.

The ratio significantly increased to 50.41 by December 31, 2021, reflecting a substantial improvement in the company's ability to generate revenue from its fixed assets. This sharp increase may indicate increased sales or better asset management during the year.

However, there was a notable drop in the fixed asset turnover ratio to 8.74 by December 31, 2022. This decline could signal possible inefficiencies in asset utilization or changes in the company's operations impacting its ability to generate revenue from its fixed assets.

For December 31, 2023, and December 31, 2024, the data indicates "—", signifying that the fixed asset turnover ratio is not available for those periods. This lack of data for consecutive years makes it challenging to assess the company's asset utilization efficiency during those times.

Overall, the significant fluctuations in the fixed asset turnover ratio of Halozyme Therapeutics Inc warrant further investigation into the company's operational changes, investment in fixed assets, and overall financial performance during the respective periods.